These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6407653)

  • 1. Erythromycin estolate and jaundice.
    Inman WH; Rawson NS
    Br Med J (Clin Res Ed); 1983 Jun; 286(6382):1954-5. PubMed ID: 6407653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythromycin jaundice: diagnosis by an in vitro challenge test.
    Cooksley WG; Powell LW
    Aust N Z J Med; 1977 Jun; 7(3):291-3. PubMed ID: 269690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatocellular jaundice due to erythromycin estolate].
    Zlotnick A
    Harefuah; 1978 Aug; 95(3-4):127-8. PubMed ID: 700498
    [No Abstract]   [Full Text] [Related]  

  • 4. Jaundice due to erythromycin estolate.
    Lunzer MR; Huang SN; Ward KM; Sherlock S
    Gastroenterology; 1975 May; 68(5 Pt 1):1284-91. PubMed ID: 1126604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases.
    Zafrani ES; Ishak KG; Rudzki C
    Dig Dis Sci; 1979 May; 24(5):385-96. PubMed ID: 456225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythromycin propionate and estolate.
    Farre M
    Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648
    [No Abstract]   [Full Text] [Related]  

  • 8. Selection of an oral erythromycin product.
    Fraser DG
    Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholestatic jaundice in patients treated with erythromycin estolate.
    HAVENS WP
    JAMA; 1962 Apr; 180():30-2. PubMed ID: 13905478
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C; Noguerado A; Hidalgo S; Escudero V
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
    Gafter U; Mandel EM; Weiss S; Djaldetti M
    N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxic jaundice due to propionyl erythromycin ester lauryl sulphate ("Ilosone").
    REED C; RITCHIE F
    Med J Aust; 1962 May; 49(i)():810-2. PubMed ID: 14037477
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythromycin estolate to remain on market.
    FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythromycin estolate hepatotoxicity.
    Lloyd-Still JD; Sherman JO; Boggs J; Demers LM
    Am J Dis Child; 1978 Mar; 132(3):320. PubMed ID: 629252
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatotoxicity of erythromycin estolate during pregnancy.
    McCormack WM; George H; Donner A; Kodgis LF; Alpert S; Lowe EW; Kass EH
    Antimicrob Agents Chemother; 1977 Nov; 12(5):630-5. PubMed ID: 21610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-benefit equation for erythromycin estolate.
    LeBel M
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
    Welling PG; Elliott RL; Pitterle ME; Corrick-West HP; Lyons LL
    J Pharm Sci; 1979 Feb; 68(2):150-5. PubMed ID: 423080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis caused by various derivatives of erythromycin].
    Funck-Brentano C; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatotoxicity of erythromycin derivatives.
    Pessayre D; Benhamou JP
    Br Med J; 1979 May; 1(6174):1357. PubMed ID: 445081
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.